Promising Long-Term Outcomes from Phase 3 HERIZON-GEA-01 Trial of Ziihera® in Advanced Gastric Cancer

Recent data from the Phase 3 HERIZON-GEA-01 trial, published in the prestigious New England Journal of Medicine, present groundbreaking results regarding the use of Ziihera® (zanidatamab-hrii) in treating HER2-positive gastroesophageal adenocarcinoma (GEA). This extensive clinical study showcases the remarkable effectiveness of Ziihera® when combined with standard chemotherapy, along with or without the PD-1 inhibitor Tevimbra® (tislelizumab), as a treatment option for patients with locally advanced or metastatic GEA.

The HERIZON-GEA-01 trial was a comprehensive global study that enrolled 914 participants across over 225 sites in more than 30 countries, providing substantial insights into the efficacy and safety profiles of zanidatamab. The published findings indicate that treatment regimens containing Ziihera® not only achieved statistically significant improvements in progression-free survival (PFS) but also in overall survival (OS) when compared to traditional therapies like trastuzumab combined with chemotherapy.

According to the trial logs, the combination therapy exhibited an impressive median PFS of 12.4 months compared to 8.1 months for standard treatments (HR 0.63-0.65). Moreover, the combination of Ziihera® with tislelizumab demonstrated a noteworthy median OS of 26.4 months against 19.2 months with trastuzumab plus chemotherapy (HR 0.72). Such findings suggest that patients receiving zanidatamab-containining therapies can anticipate longer survival times, which is particularly vital given the historically limited long-term outcomes associated with advanced GEA.

A significant aspect of these findings is the trial's subgroup analyses, focusing on varied patient characteristics including PD-L1 expression status. Remarkably, the combination therapy showed beneficial outcomes across both PD-L1-positive and PD-L1-negative patients. This is especially significant, considering that those with PD-L1-negative tumors typically have seen fewer benefits from existing PD-1-targeted therapies.

Dr. Kohei Shitara, co-lead author of the publication, emphasized the importance of these results for improving clinical practice. The expansive subgroup analyses lend further credibility to the consistency and durability of the survival benefits associated with Ziihera® regimens. With historical challenges in achieving beneficial long-term results for this patient population, these findings mark a significant advancement.

Furthermore, assessments of the safety profile of zanidatamab-containing combinations affirmed that observed adverse reactions were consistent with those typically recognized in existing therapies. Reported gastrointestinal events, including diarrhea, largely occurred early in treatment and usually did not lead to treatment discontinuation. Such data supports the notion that the regimen is not only effective but also manageable for patients.

Jazz Pharmaceuticals, the organization behind the development of Ziihera®, is actively working to submit these impactful results to the National Comprehensive Cancer Network (NCCN) for potential inclusion in their Clinical Practice Guidelines, advocating for the consideration of zanidatamab as a standard treatment option in HER2-positive GEA.

In the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, further presentations on PD-L1 subgroup analyses will delve deeper into the impact of zanidatamab-containing regimens, including more comprehensive insights into PFS and OS metrics based on PD-L1 expression.

In conclusion, the HERIZON-GEA-01 trial results offer fresh hope for patients battling HER2-positive GEA. With consistent and durable survival outcomes reported, Ziihera® (zanidatamab-hrii) combined with traditional chemotherapy and tislelizumab presents a compelling new direction in targeted cancer therapy. These results not only change the landscape of treatment options available but also enhance the overall prognostic outlook for patients suffering from this aggressive cancer subtype.